Tykerb shows efficacy in first-line HER2-positive breast cancer
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's anticancer Tykerb/Tyverb (lapatinib) has led to an increase in progression-free survival (PFS) in a subset of HER2-positive patients in the largest first-line trial of the drug so far, which was recently presented at the San Antonio Breast Cancer Symposium.